New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™

Data ReadoutpositiveAdvanceAD-Tx™Positive

AI Analysis

Summary

A study highlights clinical need for molecular guidance in atopic dermatitis treatment selection, demonstrating 94% patient interest in molecular testing to identify more effective systemic therapies, supporting the value of Moleac's AdvanceAD-Tx™ diagnostic.

Outcome Details

Study showed 94% of patients open to new systemic therapy expressed interest in molecular testing; more than half of patients using targeted systemic therapies modified treatment due to lack of efficacy

Importance:5/10

Sentiment:

0.60

atopic dermatitismolecular testingtargeted therapydiagnosticunmet need

Related Companies

$MOLN

Read the original article

Published by PR Newswire Pharma on September 24, 2026 8:30 PM

Read Original